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Introduction
Gene patents are a class of intellectual property that give 
the patentee rights to the specifi c sequences in the claims 
of a patent, providing the exclusive right to make, use, 
sell, and import a molecule consisting of a claimed 
sequence. In 2001, the US patent oﬃ  ce issued formal 
guidelines on what is acceptable patent material in the 
human genome. It stated that DNA is eligible if it is 
‘isolated from its natural state and processed through 
purifying steps that separate the gene from other 
molecules naturally associated with it.’ Th ese guidelines 
specifi ed that any gene or sequence patent also needs to 
show ‘specifi c, credible, and substantial utility’ [1]. To 
date, there are over 40,000 patents on DNA molecules 
[2,3], including those on the breast and ovarian cancer 
genes BRCA1 and BRCA2 [4], indicating that patents on 
DNA are a widespread and signifi cant class of intellectual 
property that have increased consistently since the 1980s 
(Figure 1).
Some DNA patents are for a very specifi c series of 
nucleotides (such as 5’-ATGCGACGGATCGATC-3’) or 
an exact chemical structure (such as a DNA molecule 
modifi ed with a fl uorescent probe), but diagnostic DNA-
based patents have broader claims [5]. Th ese patents are 
used to fi nd mutations in various disease-related genes, 
and the specifi ed DNA sequence as well as any other 
similar sequence are often covered within the patent 
claim. Th is is because there are many (at least [(2N) - 1]) 
possible combinations of mutations for a gene [6]. 
Diagnostic gene patents are therefore written to fi nd any 
known or unknown variation of a gene. For example, in 
the Association of Molecular Pathologists (AMP) v. 
Myriad case, the broadest intellectual property rights on 
BRCA sequences come from several related claims in 
patent 5,747,282:
Claim #1. An isolated DNA coding for a BRCA1 poly-
peptide, said polypeptide having the amino acid sequence 
set forth in SEQ ID NO:2 (the BRCA1 cDNA).
Claim #2. Th e isolated DNA of claim 1, wherein said DNA 
has the nucleotide sequence set forth in SEQ ID NO:1 (the 
BRCA1 gene).
Claim #5. An isolated DNA having at least 15 nucleotides 
of the DNA of claim 1
Claim #6. An isolated DNA having at least 15 nucleotides 
of the DNA of claim 2.
In 2010, in the fi rst ruling on AMP v. Myriad, a US 
District Court stated that all of these patent claims were 
invalid and that isolated DNA is ‘not patentable subject 
matter’. Th en, in 2011, the US Court of Appeals for the 
Federal Circuit overturned this ruling (2 to 1 decision) 
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and stated that an isolated DNA molecule is ‘markedly 
diff erent’ from native genomic DNA and that fragments 
of the BRCA genes can be patented. After a re-hearing in 
light of another case (Mayo v. Prometheus), the same 
decision was issued by the Federal Circuit in August 
2012. Recently, the Supreme Court decided to hear 
arguments in the case, opening a re-examination of the 
lower courts’ decisions and rationale on these gene 
patents and their claims.
Notably, the Federal Circuit’s decision declared that 
even a short, isolated DNA molecule such as ‘ACGT’ is 
diff erent from the ‘NNNNN-ACGT-NNNNN’ present 
within a chromosome (AMP v. Myriad, Federal Circuit 
2012), because it will not be connected to a sugar via a 
phosphodiester bond and will have a hydroxyl group 
instead of a bond to a phosphate (Figure 2). Th us, even a 
15 nucleotide fragment of DNA in Claim #6 from Patent 
‘282 is claimed to be ‘markedly diff erent’. However, we 
observe that the Court’s ruling is overly broad for at least 
three reasons. First, it relies on the sequences having 
chemical features and side-chains that are not actually 
present in the patents (Figure  2): the claims are for a 
linear series of nucleotides, not a specifi c chemical 
structure. Second, if allowed to be so broad, these claims 
could also create a monopoly on all epigenetic and 
chemical variations of these sequences. Th ird, and 
perhaps most importantly, the non-specifi city of 15mer 
sequences creates unclear infringement liability that has 
been even noted by the Court. Specifi cally, Judge Bryson 
declared that claim 6 ‘is so broad that it includes products 
of nature (the BRCA1 exons) and portions of other genes. 
... Th e other claim to a short segment of DNA, claim 5 of 
the ‘282 patent, is breathtakingly broad’ (AMP v. Myriad, 
Federal Circuit 2012). To date, however, there has not 
been a genome-wide analysis of the uniqueness of 15mer 
sequences in patented genes.
Establishing the uniqueness of gene patents in DNA 
and cDNA could potentially have a large impact on the 
interpretation of these patents [7,8]. Previous work has 
examined Claim #5 with respect to other cDNAs on one 
chromosome (Chr1), and used these data to estimate that 
15 infringing 15mers might exist for any cDNA [9]. 
However, these studies compared the likely uniqueness of 
cDNAs on the basis of an average degeneracy of the 
genetic code, leaving open the issue of exact DNA 
matches in the coding regions of genes and the genome. 
Also, a fi rst estimate, made in 2005, calculated that 18% 
patents have emerged since (Figure 1). Th ese results have 
been challenged in recent work [8], which has demon-
strated that some gene patents for genetic sequences do 
not contain the DNA fragments within the actual claims. 
Th us, we sought to examine the current landscape of 
gene patents using empirical, exact matches to known 
genes that were confi rmed to be present in patent claims, 
ranging from sequences of 15 nucleotides (15mers) to the 
full lengths of all patented DNA fragments.
Figure 1. Increasing number of DNA-based patents. We searched 
for any US patent that has DNA sequences present in the claims since 
1983 and observed a continual increase of DNA patents, with the 
greatest increase around the time of the completion of the human 
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Figure 2. Court-proposed molecular points of distinction that 
allow claims on isolated DNA sequences. On the basis of two 
molecular changes (small circles), speciﬁ cally to a single phosphate 
and one hydroxyl group, the Federal Circuit suggested that a new 
DNA fragment (right) is patentable subject matter. However, such 
molecular structures rarely appear in gene patents, and they are not 
present in the BRCA patents.
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of human genes were patented [10], but many new DNA 
Results
We fi rst examined the incidence with which 15mers 
(k = 15) from a given gene matched 15mers in other genes 
using the most recent Consensus Coding Sequences 
(CCDS) database [11] of 18,382 high-confi dence genes 
(see Methods and data). We incrementally divided each 
gene into k-mers (of between 15 and 1,000 nucleotides) 
and used the Bowtie alignment algorithm [12] to report 
every instance of a k-mer from one gene that perfectly 
matched the sequence of another gene. Our data showed 
that every gene in the CCDS database had a 15mer that 
matched the sequence of at least one other gene 
(Figure 3a). Th e number of matching genes ranged from 
as few as 5 (for MTRNR2L7) or 689 (for BRCA1) to as 
high as 7,688 (for TTN), corresponding to 0.01%, 4%, and 
42% of all genes in the human genome. Th ese results 
demonstrated that short patent sequences are extremely 
non-specifi c and that a 15mer patent claim from one 
gene will always ‘cross-match’ and patent a portion of 
another gene as well.
We then examined the distribution of ‘cross-matches’ 
for varying k-mers across all human genes. We found that 
the number of matches decreased as the k-mer size 
increased, showing an inversely proportional relationship 
of sequence uniqueness and k-mer size (Figure  3b). 
Notably, even 1,000 nucleotide fragments from known 
genes could still match 117 other genes, showing that 
long gene fragments can still show substantial non-
specifi city. We then used the same alignment criteria to 
examine the uniqueness of the entire human genome 
(beyond just coding regions), and we found that 99.999% 
of 15mers in the human genome are repeated at least 
twice (see Methods and data). Th ese data confi rm the 
fi ndings of previous studies that showed little sequence 
specifi city for small k-mers in the human genome [13-
15], but our data show for the fi rst time that this global 
non-specifi city of 15mers and longer k-mers impacts all 
gene patents, including those on BRCA1 and those 
claiming non-coding areas of the genome.
We next examined claimed sequences from existing 
gene patents, which spanned a wide range of sizes 
(Figure  4). We used sequences from published patent 
claims in the Cambia patent database (see Methods and 
data) and aligned them to the human CCDS gene set 
using the Basic Local Alignment Search Tool (BLAST). A 
previous analysis of patented genes carried out in 2005 
estimated that 18% of known genes in the human genome 
were patented [10], but a recent study suggested that this 
estimate could be infl ated as some sequences are not 
found in the patents’ claims [8]. When we used the same 
criteria (150-nucleotide match, e-value = 0) to search the 
most recent Cambia database, ensuring that the 
sequences were actually present in the patents’ claims 
(nt-inClaims.fsa, see Methods and data), we found that 
21% (3,945/18,382) of human genes are currently claimed 
when these stringent parameters are applied. When we 
repeated this analysis with more commonly used BLAST 
parameters (e-value <0.05), we found that claimed 
sequences matched 9,361 (41%) of human genes (Addi-
tional fi le 1). Both results, using relatively stringent 
criteria, indicate an increase in patented genes since 2005 
and show that current gene patents cover almost half of 
all known genes.
Additionally, when we took existing gene patents and 
matched their 15mers to known genes, we found that 
100% of known genes have at least one 15mer claimed in 
a known patent. Current gene patents were observed to 
match each gene many times, with 1,295 matches to 
other genes on average (standard deviation 1,208). When 
we examined the amount of total sequence space in 
human genes that is covered by 15mers in claims from 
current patents (Additional fi le 2), we found 58 patents 
whose claims covered at least 10% of the bases of all 
human genes. Th e top patent was US7795422, whose 
claims’ sequences matched 91.5% of human genes. 
Interestingly, we also observed a patent for improving 
bovine traits (US7468248) with explicit claims for 15mers 
that matched 84% of human genes. Th is patent was not 
even aimed at any human sequence, yet covered a 
majority of human genes once we examined the claim’s 
matches at the 15mer scale.
Discussion
Th ese results have striking implications for the AMP v. 
Myriad Genetics case, gene patent litigation, and other 
patent legislation. Th e demonstrated non-specifi city of 
sequence uniqueness across the genome suggests that the 
Supreme Court should use this case to clarify the law on 
gene patents. If patent claims that use these 15mer or 
other short k-mer sizes are enforced, it could potentially 
create a situation where a piece of every gene in the 
human genome is patented by a phalanx of competing 
patents, with potentially harmful consequences for genetic 
testing laboratories and research groups perform ing 
targeted sequencing on any gene, in virtually all species.
Our data show that currently claimed nucleotide 
sequences in US patents cover at least 41% of existing 
genes, as identifi ed by BLAST alignment matches, and as 
many as 100% when allowing for 15mers. We also 
observed a large number of cross-kingdom exact matches 
of 15mers, indicating that not only human genetic 
sequences are in play: entire patent families from plant 
genomics can similarly claim the majority of the human 
genome. As both plant and animal patents claim short 
sequences, as well as those with low homology (45 to 
55%), any claimed sequence will inevitably match many 
others. Yet, importantly, we observe that there is no ideal 
k-mer size that will preclude matches with another gene 
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Figure 3. Total matches and average number of other genes patented plotted against k-mer size. We searched for matches of a given 
fragment size (k-mer) of all genes relative to all other genes. We fragmented each Consensus Coding Sequence (CCDS) gene (n = 18,382) into 
variable lengths (x-axis) and then (a) summed the percentage of genes that would match another CCDS gene (y-axis). (b) We then examined, for 
each gene, the number of other genes that would match any of its own k-mers. We plotted the distribution of these cross-gene matches (y-axis) 
across all CCDS genes, with a varying k-mer size (x-axis). Boxplots show the distribution of the data as the median (middle line), 75th and 25th 
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in the genome. Thus, the non-specificity needed for diag-
nostic patents to find any mutated sequence of one gene 
expands their property rights to hundreds or thousands 
of other genes.
Some have commented that whole-genome sequencing 
(WGS) might avoid some of these infringement problems 
[8], as no targeted fragment that contains a patented 
sequence is specifically isolated when shotgun-based 
approaches are used for sequencing. There is, however, 
no specific case precedent that yet supports this con-
clusion, and as such, legal ambiguities still affect WGS. 
These infringement risks are also still very clear for PCR-
based or enrichment-capture strategies, which directly 
overlap with these patents by enriching for a molecule 
that contains BRCA1 or the targets of other patented 
genes. These targeted methods currently represent the 
vast majority of clinical sequencing for diagnostic 
medical decisions in molecular pathology, and they will 
likely be used for a long time as validation technology for 
any WGS approaches.
These claims’ non-specificity highlight a large problem 
with gene patents, but there are at least four other 
potential dangers inherent to these patents. First, since 
almost all claimed genetic sequences from gene patents 
are simple DNA sequences that lack atomic-scale 
molecular structures, the patenting of specific gene 
sequences could prevent their use in other modalities of 
research. For example, patents could prevent work 
involving epigenetic and transcriptional studies of a gene 
in which some bases contain methyl groups (for example, 
a comparison of TACTGG and TACmTGG) or hydroxyl-
methyl groups, both of which are important for cancer 
[16] and RNA regulation [17]. Second, patents on one 
gene can prevent research on any pseudogene of the 
original gene, such as BRCA1’s pseudogene (BRCA1P1), 
even though pseudogenes can have their own indepen-
dent function in a cell. Third, if these 15mer and other 
gene patent claims are allowed, new regions of the human 
genome that are still being discovered and annotated 
could be patented as soon as they are sequenced. Last, 
understanding pleiotropy for any gene depends on the 
ability to examine a gene in every context, and one patent 
on a gene’s single known function limits any ability to 
discover the gene’s many other possible functions. For 
example, beyond breast and ovarian cancer, there are 19 
other cancers in The Cancer Genome Atlas [18] that are 
also associated with common mutations in BRCA1 
(Figure 5), yet only Myriad Genetics has the right to an 
isolated molecule containing BRCA1 from any of these 
patients. Taken together, gene patents represent a sharp 
conflict between the public goods of medical knowledge 
and improved health and the private goods of rewarding 
innovation and entrepreneurial risk-taking.
Fortunately, there is precedence in US history for 
resolving such a medical-legal conflict. In 1992, a US 
patent was issued (#5,080,111) for a ‘self-sealing episcleral 
incision’, and this patent required a license of $4.00 per 
operation for any doctor to use the method. A lawsuit 
was filed against the patent by the American Medical 
Association (AMA), which strongly condemned ‘the 
patenting of medical and surgical procedures’ and began 
to work with Congress to outlaw the practice. The AMA 
argued that the best surgical techniques should not be 
denied to patients, simply because of legal reasons or 
fees. In 1995, the United States Code was changed 
accord ingly, to add language that exempted any ‘patient, 
physician, licensed healthcare practitioner, or a health 
care entity from infringement of a patented medical or 
surgical procedure, therapy, or diagnosis’. Thus, any 
surgeon could still patent a new method and stake claim 
as the inventor, but the patients’ need to get access to the 
best medical care out-weighed the infringement of the 
intellectual property rights of surgeons.
Now that the era of genomic medicine is here, the US 
Supreme Court has the chance to shape the balance of 
the medical good and inventor protection. Given the 
falling price of genome sequencing and targeted re-
sequen cing, and the ubiquity of the genomics technolo-
gies, the urgency to resolve this uncertainly around gene 
patents has never been more salient. Failure to resolve 
these ambiguities perpetuates a direct threat to ‘genomic 
liberty’, or the right to examine one’s own DNA. Our 
analysis and data provide strong evidence that the 
Figure 4. Size distribution of gene patents. We examined the total 
number of base pairs (bp) included in the claims of each US Patent. 
The mean amount of sequence claimed is 1,781 bp with the median 
of 21,950 bp. This disparity indicates that there are many patents that 
claim a large amount of sequence.
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Supreme Court and Congress should limit the patenting 
of existing nucleotide sequences because of their broad 
scope and non-specificity in the human genome. Finally, 
we suggest that a research exemption or limited liability 
for patent infringement be implemented, as has been 
done for surgical techniques, which could craft a func-
tional balance between the rights of inventors and the 




We used gene sequences from the CCDS database, which 
were downloaded from the NCBI web site [19]. This is a 
curated set of high-confidence genes prepared by an 
international consortium [11]. It contains 18,382 genes 
having a total of 26,355 isoforms. For this analysis, we 
used the longest isoform of each gene as a single, 
representative sequence for that gene.
Tumor data from The Cancer Genome Atlas
We used the public database from The Cancer Genome 
Atlas (TCGA) [18], and specifically the query and search 
tool at Memorial Sloan Kettering Cancer Center (MSKCC) 
[20]. We used the query ‘BRCA1’ for the database search. 
Data queried on 9 March 2013.
Claim-specific sequence identification
Patents in the inClaims subset of the Cambia [21] patent 
sequence database were downloaded from [22]. This 
database has been curated to include all of the sequences 
from US Patents that are specifically contained within the 
claims of the inventions, and we validated 25 of these 




For the comparisons of k-mers between genes, we used 
Bowtie (v0.12.5) to report all of the matches for each 
query. Each CCDS gene was split into all overlapping k-
mers of the designated length and these sequences were 
searched against all of the other genes.
Long-read alignments
The comparison of patents to genes was performed using 
the criteria used by Jensen and Murray [10]; specifically 
using BLAST version 2.2.25+ [23] to match at least 150 
Figure 5. Patients with other cancer types who carry BRCA1 mutations. We used data from The Cancer Genome Atlas (TCGA) to examine the 
percentage of patients with other tumor types who show deleterious mutations (missense, nonsense, copy-number, and structural variations) in 
their BRCA1 gene. We found that ovarian and breast cancers are only 2 of 21 total cancer types likely to be associated with relevant mutations in 
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nucleotides and an e-value of 0. This was performed 
using the BLAST command: blastn -evalue 1e-307 
-word_size 150.
In addition, the criteria of e-value <0.05 was used, 
which is a typical set of parameters for BLAST. The 
command was: blastn -evalue 0.05. For the exact 
matching of 15 bp sequences, Bowtie was used. The 
bowtie command was: bowtie -f -a -best -v 0.
Mutational complexity estimate
For the calculations in our text about mutational 
complexity, we show that for a gene with N mutations, 
there are [(2N) - 1] combinations of mutated forms of that 
gene. For example, given a sequence with ten bases, 
where ‘=’ represents an un-modified base pair, where 
three mutations (A,G,T) exist, there are [(2N)  -  1]  = 
[23 - 1] = [8 - 1] = 7 possible combinations.
These seven possible mutated forms that are different 










AMA, American Medical Association; AMP, Association of Molecular 
Pathologists; BLAST, Basic Local Alignment Search Tool; CCDS, Consensus 
Coding Sequences; WGS, whole-genome sequencing.
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